Effectiveness of Rexulti (Brexpiprazole) for Dementia Psychosis
Based on the available evidence, I can provide information about brexpiprazole's effectiveness for agitation in Alzheimer's dementia, though the sources do not specifically address broader dementia psychosis.
Clinical Trial Evidence
Agitation in Alzheimer's Dementia
A recent randomized controlled trial specifically evaluated brexpiprazole for agitation in Alzheimer's dementia (AAD) in Japanese patients [3]. The study findings include:
Primary Efficacy Results:
- Both brexpiprazole 1 mg/day and 2 mg/day demonstrated statistically significant improvement compared to placebo [3]
- 2 mg dose: Least squares mean difference of -7.2 points on the Cohen-Mansfield Agitation Inventory (CMAI) total score (95% CI: -10.0 to -4.3, p<0.0001) [3]
- 1 mg dose: Least squares mean difference of -3.7 points on CMAI (95% CI: -6.8 to -0.7, p=0.0175) [3]
Treatment Duration:
- The study evaluated 10 weeks of treatment [3]
- This represents the first confirmation of efficacy for the 1 mg/day dose [3]
Safety Profile
Tolerability:
- Both doses were generally well tolerated [3]
- Treatment-emergent adverse events occurred in:
- 76.8% of patients on 1 mg brexpiprazole
- 84.6% of patients on 2 mg brexpiprazole
- 73.8% of patients on placebo [3]
Important Note: The incidence of adverse events was higher compared to previous studies [3].
Limitations of Available Evidence
The available sources do not contain information about:
- Brexpiprazole's effectiveness for other aspects of dementia psychosis (such as hallucinations or delusions)
- Long-term efficacy beyond 10 weeks
- Comparative effectiveness against other antipsychotics specifically in dementia populations
- Effectiveness in non-Alzheimer's types of dementia
Context from Related Research
While not specific to dementia, brexpiprazole has shown efficacy as an augmentation agent in treatment-resistant depression, with significant response and remission rates compared to placebo [2]. The optimal dose for schizophrenia has been identified as 3.36 mg/day [5], which is higher than the doses studied for dementia agitation.
According to available evidence, brexpiprazole appears effective for treating agitation in Alzheimer's dementia, but more research is needed to establish its broader effectiveness for dementia psychosis symptoms.